Biofrontera Inc. Additional Paid in Capital, Common Stock
Biofrontera Inc. (BFRI) had Additional Paid in Capital, Common Stock of $90.20 million as of 2021-12-31, per its 10-K filed 2022-04-11.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2022-04-11
- 2021-12-31: Additional Paid in Capital, Common Stock $90.20M.
- 2021-09-30: Additional Paid in Capital, Common Stock $46.99M.
- 2020-12-31: Additional Paid in Capital, Common Stock $46.99M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2021-12-31 | $90.20M 10-K · filed 2022-04-11 |
| 2021-09-30 | $46.99M 10-Q · filed 2021-11-30 |
| 2020-12-31 | $46.99M 10-K · filed 2022-04-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |